Comprehensive chemical proteomics for target deconvolution of the redox active drug auranoﬁn

Amir Ata Saeia, b, Hjalmar Gullbergb, 1, Pierre Sabatierb, 1, Christian M. Beuschb, 1, Katarina Johanssonc, d, Bo Lundgrenb, Per I. Arvidssone, Elias S.J. Arnérb, Roman A. Zubarevf, 1

Keywords: Ligand, Mechanism of action, Protein expression, Melting temperature, Target

**Abstract**

Chemical proteomics encompasses novel drug target deconvolution methods in which compound modiﬁcation is not required. Herein we use Thermal Proteome Profiling, Functional Identiﬁcation of Target by Expression Proteomics and multiplexed redox proteomics for deconvolution of auranoﬁn targets to aid elucidation of its mechanisms of action. Auranoﬁn (Ridaura®) was approved for treatment of rheumatoid arthritis in 1985. Because several clinical trials are currently ongoing to repurpose auranoﬁn for cancer therapy, comprehensive characterization of its targets and effects in cancer cells is important. Together, our chemical proteomics tools conﬁrmed thioredoxin reductase 1 (TXNRD1, EC:1.8.1.9) as a main auranoﬁn target, with perturbation of oxidoreductase pathways as the top mechanism of drug action. Additional indirect targets included NFKB2 and CHORDC1. Our comprehensive data can be used as a proteomic signature resource for further analyses of the effects of auranoﬁn. Here we also assessed the orthogonality and complementarity of different chemical proteomics methods that can furnish invaluable mechanistic information and thus the approach can facilitate drug discovery efforts in general.

1. Introduction

Chemical proteomics has recently developed a set of tools for prediction of drug targets and determination of action mechanisms, in which drug modiﬁcation is no longer required. These tools include Thermal Proteome Profiling (TPP) [1] and Functional Identiﬁcation of Target by Expression Proteomics and multiplexed redox proteomics for deconvolution of auranoﬁn targets to aid elucidation of its mechanisms of action. Auranoﬁn (Ridaura®) was approved for treatment of rheumatoid arthritis in 1985. Because several clinical trials are currently ongoing to repurpose auranoﬁn for cancer therapy, comprehensive characterization of its targets and effects in cancer cells is important. Together, our chemical proteomics tools conﬁrmed thioredoxin reductase 1 (TXNRD1, EC:1.8.1.9) as a main auranoﬁn target, with perturbation of oxidoreductase pathways as the top mechanism of drug action. Additional indirect targets included NFKB2 and CHORDC1. Our comprehensive data can be used as a proteomic signature resource for further analyses of the effects of auranoﬁn. Here we also assessed the orthogonality and complementarity of different chemical proteomics methods that can furnish invaluable mechanistic information and thus the approach can facilitate drug discovery efforts in general.

Abbreviations: CETSA, Cellular Thermal Shift Assay; FITEXP, Functional Identiﬁcation of Target by Expression Proteomics; PISA, Proteome Integral Solubility Alteration assay; TPP, Thermal Proteome Profiling; TR-TPP, Temperature Range-Thermal Proteome Profiling; TXNRD1, Thioredoxin Reductase 1

Corresponding author. Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65, Stockholm, Sweden.

E-mail address: Roman.Zubarev@ki.se (R.A. Zubarev).

These authors contributed equally to this work.

https://doi.org/10.1016/j.redox.2020.101491

Received 12 February 2020; Received in revised form 17 February 2020; Accepted 2 March 2020

Available online 03 March 2020

2213-2317/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
after long-term (usually 48 h) incubation of living cells with the drug at a LC50 concentration. FITExP is based on the “the central dogma of expression proteomics”, which postulates that drug targets and main mechanistic proteins have the highest specific modulation of their expression levels upon a perturbation. FITExP has been used to predict targets and mechanisms of action of chemotherapeutics [2], metallo-drugs [7], and nanoparticles [8]. Recently, we have shown that drug target deconvolution in FITExP can be improved by combining the proteomic data from treated matrix-detached (dying) and matrix-attached (surviving) cells [9]. We have further developed a tool called ProTargetMiner (http://protargetminer.genexplain.com), which is based on FITExP but employs a sizeable (> 50 drugs) proteome signature library of anticancer compounds for highly specific target identification [10].

Auranofin (Ridaura®) is a gold-containing molecule, approved by Food and Drug Administration (FDA) of the USA for treatment of rheumatoid arthritis. Given its potent antitumor activity [11], several clinical trials (ovarian cancer NCT03456700, chronic lymphocytic leukemia NCT03456700 and lung cancer NCT03456700) are underway, aiming to repurpose auranofin for cancer therapy [12,13]. Auranofin binds to its cognate selenoprotein target thioredoxin reductase 1 (TXNRD1) [14]. However, a controversy exists regarding cellular targets of auranofin, and several alternative action mechanisms have been proposed, some of which include inhibition of redox enzymes including primarily TXNRD1 [15-18], inhibition of protein kinase C [19], inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) [20], and protein tyrosine phosphatases [21]. Proteasomal deubiquitinase activities can also be inhibited, at least at higher concentrations of auranofin [15,22]. At the same time, potentially important off-targets of auranofin remain unexplored. To shed light on these issues, we decided to employ the above mentioned chemical proteomics approaches to characterize auranofin's cellular effects and deconvolute its targets in an unbiased de novo manner. Since auranofin is known to affect cellular redox balance, we also decided to add multiplexed redox proteomics to the chemical proteomics toolbox [23]. An overview of the three methods used and the complementary type of information gained from them is shown in Fig. 1.

2. Materials and methods

2.1. Cell culture

Human colorectal carcinoma HCT116 cells (ATCC, USA) were grown in McCoy's 5A modified medium (Sigma-Aldrich, USA) supplemented with 10% FBS superior (Biochrom, Berlin, Germany), 2 mM l-glutamine (Lonza, Walkersville, MD, USA) and 100 units/mL penicillin/streptomycin (Gibco, Invitrogen) and incubated at 37 °C in 5% CO2. Human skin malignant melanoma cells A375 and human colon carcinoma cells RKO were grown under the same conditions in DMEM. Cells are known to a variety of drugs [7], and nanoparticles [8]. Recently, we have shown that drug target deconvolution in FITExP can be improved by combining the proteomic data from treated matrix-detached (dying) and matrix-attached (surviving) cells [9]. We have further developed a tool called ProTargetMiner (http://protargetminer.genexplain.com), which is based on FITExP but employs a sizeable (> 50 drugs) proteome signature library of anticancer compounds for highly specific target identification [10].

Auranofin (Ridaura®) is a gold-containing molecule, approved by Food and Drug Administration (FDA) of the USA for treatment of rheumatoid arthritis. Given its potent antitumor activity [11], several clinical trials (ovarian cancer NCT03456700, chronic lymphocytic leukemia NCT03456700 and lung cancer NCT03456700) are underway, aiming to repurpose auranofin for cancer therapy [12,13]. Auranofin binds to its cognate selenoprotein target thioredoxin reductase 1 (TXNRD1) [14]. However, a controversy exists regarding cellular targets of auranofin, and several alternative action mechanisms have been proposed, some of which include inhibition of redox enzymes including primarily TXNRD1 [15-18], inhibition of protein kinase C [19], inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) [20], and protein tyrosine phosphatases [21]. Proteasomal deubiquitinase activities can also be inhibited, at least at higher concentrations of auranofin [15,22]. At the same time, potentially important off-targets of auranofin remain unexplored. To shed light on these issues, we decided to employ the above mentioned chemical proteomics approaches to characterize auranofin's cellular effects and deconvolute its targets in an unbiased de novo manner. Since auranofin is known to affect cellular redox balance, we also decided to add multiplexed redox proteomics to the chemical proteomics toolbox [23]. An overview of the three methods used and the complementary type of information gained from them is shown in Fig. 1.

2. Materials and methods

2.1. Cell culture

Human colorectal carcinoma HCT116 cells (ATCC, USA) were grown in McCoy's 5A modified medium (Sigma-Aldrich, USA) supplemented with 10% FBS superior (Biochrom, Berlin, Germany), 2 mM l-glutamine (Lonza, Walkersville, MD, USA) and 100 units/mL penicillin/streptomycin (Gibco, Invitrogen) and incubated at 37 °C in 5% CO2. Human skin malignant melanoma cells A375 and human colon carcinoma cells RKO were grown under the same conditions in DMEM. Cells are known to a variety of drugs [7], and nanoparticles [8]. Recently, we have shown that drug target deconvolution in FITExP can be improved by combining the proteomic data from treated matrix-detached (dying) and matrix-attached (surviving) cells [9]. We have further developed a tool called ProTargetMiner (http://protargetminer.genexplain.com), which is based on FITExP but employs a sizeable (> 50 drugs) proteome signature library of anticancer compounds for highly specific target identification [10].

Auranofin (Ridaura®) is a gold-containing molecule, approved by Food and Drug Administration (FDA) of the USA for treatment of rheumatoid arthritis. Given its potent antitumor activity [11], several clinical trials (ovarian cancer NCT03456700, chronic lymphocytic leukemia NCT03456700 and lung cancer NCT03456700) are underway, aiming to repurpose auranofin for cancer therapy [12,13]. Auranofin binds to its cognate selenoprotein target thioredoxin reductase 1 (TXNRD1) [14]. However, a controversy exists regarding cellular targets of auranofin, and several alternative action mechanisms have been proposed, some of which include inhibition of redox enzymes including primarily TXNRD1 [15-18], inhibition of protein kinase C [19], inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) [20], and protein tyrosine phosphatases [21]. Proteasomal deubiquitinase activities can also be inhibited, at least at higher concentrations of auranofin [15,22]. At the same time, potentially important off-targets of auranofin remain unexplored. To shed light on these issues, we decided to employ the above mentioned chemical proteomics approaches to characterize auranofin's cellular effects and deconvolute its targets in an unbiased de novo manner. Since auranofin is known to affect cellular redox balance, we also decided to add multiplexed redox proteomics to the chemical proteomics toolbox [23]. An overview of the three methods used and the complementary type of information gained from them is shown in Fig. 1.

2. Materials and methods

2.1. Cell culture

Human colorectal carcinoma HCT116 cells (ATCC, USA) were grown in McCoy's 5A modified medium (Sigma-Aldrich, USA) supplemented with 10% FBS superior (Biochrom, Berlin, Germany), 2 mM l-glutamine (Lonza, Walkersville, MD, USA) and 100 units/mL penicillin/streptomycin (Gibco, Invitrogen) and incubated at 37 °C in 5% CO2. Human skin malignant melanoma cells A375 and human colon carcinoma cells RKO were grown under the same conditions in DMEM. Cells are routinely checked for mycoplasma contamination by PCR.

2.2. Cell viability assay

Cell viability upon compound treatment was measured using CellTiter-Blue assay (Promega) according to manufacturer protocol and the LC50s were calculated, as the concentration of compound causing 50% cytotoxicity. The measured values have been listed in Supplementary Table 1.

2.3. TR-TTP experiment in lysate

The TPP experiment was performed according to Ref. [5] with some modifications. HCT116 cells were grown, trypsinized, washed and eventually lysed by 5X freeze-thawing in liquid nitrogen. The lysates were either incubated with 500 nM of auranofin or DMSO for 2 h. The lysate was then aliquoted into 10 microtubes each. The aliquots were incubated for 3 min at 37–67 °C (37, 41, 44, 47, 50, 53, 56, 59, 63 and 67) in SimpliAmp Thermal Cycler (Thermo). After heating, samples were kept at room temperature for 3 min and subsequently immediately snap-frozen in liquid nitrogen. The sample constituents were transferred into polycarbonate thickwall tubes and centrifuged at 100,000 g at 4 °C for 20 min using Optima LE-80 ultracentrifuge (Beckman). The soluble protein fraction was carefully transferred to new Eppendorf tubes. Protein concentration was measured in the samples treated with lowest temperatures (37 and 41 °C from each replicate) using Pierce™ BCA Protein Assay Kit (Thermo), the same volume corresponding to 50 μg of protein (in samples treated with lowest temperatures) was transferred from each sample to new tubes and sample buffer (8 M urea, 1% SDS, 50 mM Tris pH 8.5) was added. DTT was added to a final concentration of 10 mM and samples were incubated for 1 h at room temperature. Subsequently, iodoacetamide was added to a final concentration of 50 mM and samples were incubated in room temperature for 1 h in the dark. The reaction was quenched by adding an additional 10 mM of DTT. Proteins were precipitated using methanol/chloroform. After precipitation of proteins using methanol/chloroform, the semi-dry protein pellet was dissolved in 25 μL of 8 M urea in 20 mM EPPS (pH 8.5) and then was diluted with EPPS buffer to reduce urea concentration to 4 M. Lysyl Endopeptidase (Wako) was added at a 1 : 100 w/w ratio to protein and incubated at room temperature overnight. After diluting urea to 1 M, trypsin (Pro-mega) was added at the ratio of 1 : 100 w/w and the samples were incubated for 6 h at room temperature. TMT10 reagents were added 4x by weight to each sample, followed by incubation for 2 h at room temperature. The reaction was quenched by addition of 0.5% hydroxyamine. Samples were combined, acidified by TFA, cleaned using Sep-Pak (Waters) and dried using a DNA 120 SpeedVac™ concentrator
Samples were then resuspended in 0.1% TFA and separated into 8 fractions using High pH Reversed-Phase Peptide Fractionation Kit (Thermo). After resuspension in 0.1% FA (Fluka), each fraction was run with a 140 min gradient.

2.4. TR-TPP experiment in living cells

Cells were treated with 2 μg/mL aurano fin for 2 h inside the flasks, and were then trypsinized, washed twice with PBS, counted and distributed in 2 million cell aliquots inside PCR tubes. After heating, for cell lysis, samples were freeze thawed 3 times. The rest of the protocol was identical to the TR-TPP experiment in lysate.

2.5. Redox proteomics experiments

Cells were treated with 3 μM aurano fin or corresponding amount of DMSO for 2 h, similar to the TR-TPP in cells and lysate, as well as deep redox proteomics. Proteins with the lowest overall sum are top candidate targets (TXNRD1 is the known cognate target). e-g, Changes in 3 top target proteins: (e) – specific expression in three cell lines in FITExP, (f) – oxidation level of top peptide (f), and (g) – melting curves in TPP experiments in cells (none of these proteins changed their stability in cell lysate). h, Top 15 proteins from each method were combined (60 proteins in total from 4 methods) and analyzed with Functional Annotation Clustering tool in DAVID. Top enriched biological pathways with minimal redundancy (fold enrichment > 5 and p < 0.01), representing the dominant mechanisms for aurano fin, are shown (n = 3 biological replicates for all experiments, TPP experiment was performed in 2 replicates. P values were calculated with two-sided student t-test, mean ± SD).

Fig. 2. Unbiased de novo prediction of aurano fin targets and mechanism space by chemical proteomics tools. a, Combining the FITExP data from three cell lines and three drugs, which was followed by identification of compound-specific proteome signatures by hierarchical clustering. Data in the heatmap is presented as mean log2 (fold change vs. control) in 3 replicates. b, Redox proteomics revealed an increase in the oxidation level of many peptide in response to aurano fin, as expected. Data is plotted as oxidation ratio upon aurano fin treatment relative to the mean oxidation ratio upon DMSO treatment. c, TPP data for proteins with ±1°C difference between the two replicates in 3 μM aurano fin treatment of HCT116 cells shows stabilization of several proteins. Some of these proteins, including GABPB1 [30], RRM1 [31,32] and SRXN1 [33] are known to be regulated by the thioredoxin system. d, The cumulative sum of individual target rankings in four different types of analysis (FITExP, TR-TPP in cells and lysate, as well as deep redox proteomics). Proteins with the lowest overall sum are top candidate targets (TXNRD1 is the known cognate target), e-g, Changes in 3 top target proteins: (e) – specific expression in three cell lines in FITExP, (f) – oxidation level of top peptide (f), and (g) – melting curves in TPP experiments in cells (none of these proteins changed their stability in cell lysate). h, Top 15 proteins from each method were combined (60 proteins in total from 4 methods) and analyzed with Functional Annotation Clustering tool in DAVID. Top enriched biological pathways with minimal redundancy (fold enrichment > 5 and p < 0.01), representing the dominant mechanisms for aurano fin, are shown (n = 3 biological replicates for all experiments, TPP experiment was performed in 2 replicates. P values were calculated with two-sided student t-test, mean ± SD).

(Aurano fin and DMSO-treated samples were pooled separately. After dilution of urea to 2 M, Lysyl Endopeptidase was added at a 1:100 w/w ratio overnight at room temperature. Urea was diluted to 1 M before trypsin addition for 6 h at 37°C. Samples were acidified by adding TFA, cleaned using SepPak and lyophilized using a vacuum concentrator. The samples were fractionated into 8 using Pierce High pH Reversed-Phase Peptide Fractionation Kit (Thermo).
2.6. FITExP experiment

For FITExP experiments, HCT116, A375 and RKO cells were treated with aurano fin for 48 h at LC50 concentrations. Methotrexate and paclitaxel were included in these experiments to increase the specificity of detection for differentially expressed proteins. In brief, cells were cultured in 6 well plates at a density of 250 k per well, allowed to detach overnight and treated with the compounds at LC50 concentrations for 48 h. After the treatment period, cells were washed with PBS and lysed with 3% SDC in amnic buuffer. Samples were sonicated for 45s, 30% amplitude, 3s on/off cycles using Branson probe sonicator. After total protein quantification using BCA assay, the protein amount in each sample was normalized. DTT was added to a final concentration of 5 mM and samples were incubated for 1 h at room temperature. Subsequently, iodoacetamide was added to a final concentration of 50 mM and samples were incubated in room temperature for 1 h in the dark. The reaction was quenched by adding an additional 10 mM of DTT. After dilution of SDC to 1.5%, digestion was performed at a ratio of 1:100 w/w overnight for Lysyl Endopeptidase. SDC was then diluted to 0.5% and trypsin was added at the same ratio for 6 h. Samples were acidified by TFA, cleaned using SepPak and lyophilized.

2.7. Proteomics

Proteins digests (1 μg) were analyzed in a randomized order by LC-MS/MS. Samples were loaded onto a 50 cm column (EASY-Spray,
75 μm internal diameter (ID), PepMap C18, 2 μm beads, 100 Å pore size) connected to an Easy-nLC 1000 pump (Thermo Fisher Scientific) with buffer A (0.1% formic acid in water) and eluted with a gradient reaching from 2% to 30% of buffer B (98% ACN, 0.1% FA, 2% H2O) at a flow rate of 250 nL/min. Details of all proteomic experiments have been summarized in Supplementary Table 2.

2.8. Data processing

The raw data from mass spectrometry were searched in MaxQuant, version 1.5.6.5, for quantification of proteins [24]. The Andromeda search engine [25] was run against the International Protein Index (human version UP00005640 9606, 92,957 entries). Methionine oxidation were selected as variable modifications, while cysteine carboxymethylation was set as a fixed modification (expect for redox...
2.10. Network mapping

The proteomics experiments were performed as follows: two TR-TPP in cells around auranozin LC50 concentrations (2 and 3 μM for 2 h in HCT116 cells) (data in Supplementary Tables 3 and 4, respectively), a TR-TPP in HCT116 cell lysate (500 nM for 1 h, Supplementary Table 5), a FITExP analysis with auranozin as well as methotruxate and paclitaxel as control compounds in RKO, HCT116 and A375 cells (for each drug and cell lines, at a 48 h LC50 concentration, Supplementary Table 6), and a redox proteomics analysis under the same conditions as TR-TPP (3 μM auranozin for 2 h in HCT116 cells, Supplementary Table 7). The samples from redox proteomics were fractionated to increase the proteome coverage (Supplementary Table 8).

The ranking calculations for all experiments are provided in Supplementary Tables 4-6, 8. Data from TPP experiments with 3 μM auranozin in cells and 500 nM auranozin in lysate were used for the ranking, excluding proteins with missing abundance values and with > 1 °C Tm differences between the replicates. The protein with the highest absolute mean Tm shift between the drug and vehicle treatments received rank 1, similar to other recent studies [26,27].

In the FITExP experiment that discovers the targets and mechanistic mechanisms proteins consistently regulated by a drug in a panel of cell lines [10,28], only proteins quantified over the whole dataset were used in the ranking process. Proteins were ranked based on their mean regulation in each cell line; the most regulated protein received ranking 1. The individual rankings in three cell lines were summed together, with the sums sorted in the ascending order.

In the deep redox proteomics experiment, only peptides consistently quantified in all samples were used in ranking. Oxidation ratio was calculated as the abundance of peptides labeled with the second set of TMT tags (corresponding to peptides involved in disulfide bonds) normalized by the summed abundance of the first and second labels (all peptide population). As an output, the difference in the mean oxidation level of a peptide in auranozin and DMSO treatments was calculated. In addition, the p value was also calculated (two-tailed Student’s t-test). The list of proteins was thereupon ranked twice: by the differences in oxidation ratios between drug and vehicle treatments (the highest difference received ranking 1), and by the p value. The two ranks were summed together, with the sums sorted in ascending order to obtain the final rank (Supplementary Table 8).

For each protein, all the above individual rankings were summed and sorted in ascending order to obtain the overall ranks (Fig. 2d and Supplementary Table 9). In redox proteomics, where more than one peptide could sometimes be quantified for each protein, the peptide with the best ranking was used in calculation of the cumulative rank, while other peptides from that protein were ignored.

2.11. Statistics

The TPP experiments were performed in 2 replicates. All other experiments were performed in 3 independent replicates. Two-tailed t-tests were used throughout the paper for analysis of significance.

2.12. Data availability

The LC-MS/MS raw data files and extracted peptides and protein abundances are deposited in the jPOST repository of the ProteomeXchange Consortium under the dataset identifier PXD016776 [29].

3. Results and discussion

3.1. Unbiased prediction of auranozin targets using a combination of chemical proteomics tools

Since each chemical proteomics method yields both false positives and false negatives, parallel tools must be employed to obtain a reliable list of target protein candidates, each supported by, preferably, more than one technique. Thus, a series of proteomics experiments were performed, as detailed in Materials and Methods. Fig. 2a gives an overview of the data obtained in the FITExP experiment. Each column in the heatmap represents the mean log2 (fold change vs. control) in 3 replicates. Fig. 2b shows the overall results of the redox experiment, where data is plotted as oxidation ratio upon auranozin treatment relative to the mean oxidation ratio upon DMSO treatment. The heatmap shows an increase in the oxidation level of many peptides in response to auranozin, as expected. In Fig. 2c, we plot the TPP results in cells treated with 3 μM auranozin. Only the proteins with a confident Tm (within ± 1 °C difference between the replicates) were considered.

To identify the most probable target candidates, the proteins were ranked in TPP based on the melting temperature difference (ΔTm) between auranozin and control treatments. In FITExP, the ranking was based on the absolute magnitude of consistent regulation in three cell lines, and in redox proteomics, based on the differences in the oxidation levels between the auranozin and control treatments (the top protein in each method got ranking 1). The rankings from all four experiments (TPP in cells and lysate, FITExP and deep redox proteomics) were summed up to shortlist the candidate drug targets (Fig. 2d) (proteins with the lowest overall rankings are top candidate targets; the top proteins are given in Supplementary Table 10). Although combining orthogonal chemical proteomics tools is a powerful approach in target deconvolution, one limitation is that not all proteins are quantified in all experiments (so-called missing value problem). Therefore, proteins quantified in all approaches are more likely to receive better rankings. This shortcoming will be ameliorated in the future by higher coverage of the proteome brought about by advances in mass spectrometry based proteomics.

TXNRD1 was found on the 3rd position. That the auranozin cognate target appeared among the top candidates testifies to the correctness of the performed chemical proteomics analyses, and independently validates TXNRD1 as a main auranozin target in cells. The fact highlighting the importance of combining several methods is that the highest ranking TXNRD1 received in a single analysis method was the 12th position in FITExP. The upregulation of TXNRD1 was cell-line dependent (Fig. 2e). The top detected oxidized peptide of TXNRD1 was CDYENVPTTVFPLEYGACGLSEEK, with an auranozin to DMSO oxidation ratio of 2.53 (p = 0.051) (Fig. 2f). TXNRD1 was only slightly (but reproducibly) stabilized in intact cells (1.14 °C with 3 μM and 1.02 °C with 2 μM auranozin) (Fig. 2g), but not in cell lysates. The weak stability/solubility change of TXNRD1 may be attributed to the fact that auranozin binds to its penultimate amino acid (selenocysteine), with possible transfer of gold to redox-active cysteine couples inside the protein occurring next [34]. The near-terminus binding may not induce significant change in the overall thermal stability or solubility of the molecule. The C-terminal active site motif of TXNRD1 known to bind auranozin, contains a selenocysteine that is apparently not amenable to iodoTMT labeling as we did not detect the corresponding peptide.
The top protein was NFKB2 (Nuclear factor NF-kappa-B p100 subunit). Inhibition of NF-kB activation is known to be partially responsible for the anti-inflammatory effects of auranofin [35,36], and, interestingly, NF-kB signaling is also regulated by TXNRD1 and the thioredoxin system [37–39]. Here we found that NFKB2 was upregulated by auranofin about 1.4- and 1.5-fold in HCT116 and A375 cells, respectively, but slightly down-regulated to 0.9 in RKO cells (Fig. 2e). The oxidation of the NFKB2 top peptide QCSELGICAVSVGPK in the presence of auranofin was 2.3 times higher than for DMSO (p < 0.001) (Fig. 2f). Furthermore, NF-kB2 was stabilized by 2.95 °C in cells treated with 3 μM auranofin (Fig. 2g), but no significant stabilization was found in lysate.

CHORDC1 (Cysteine and histidine-rich domain-containing protein 1) that ranked second was unexpected among the top proteins. Despite being rich in cysteine, it appears to be a novel player in the context of thiol reactive metal compounds such as auranofin, and is mostly known for being involved in HSP90 chaperone complex and stress response [40]. CHORDC1 was upregulated in HCT116 and RKO cells by 1.4- and 1.2-fold, respectively, but its expression change was insignificant in A375 cells (Fig. 2e). The cysteine in the top peptide TSDFNFLAQEGCTK (Cys211) was oxidized in the presence of auranofin 3.8-fold more than in DMSO (p = 0.019) (Fig. 2f). In TPP, CHORDC1 showed no stabilization in either cells (Fig. 2g) or lysate. Therefore, the appearance of CHORDC1 on the top of the list is mainly due to its significant oxidation shown in redox proteomics.

### 3.2. Pathway analysis reveals major auranofin mechanism

To understand the cellular pathways perturbed by auranofin, the expression data for auranofin were clustered (Fig. 3a). Expectedly, the samples first clustered according to the three cell lines and then to the treatments. The protein Cluster 6 was composed of 15 proteins which were upregulated in all three cell lines, and which grouped together regardless of the chosen number of clusters (n = 6–10). This set of proteins best mapped to “glutathione metabolic process” (4 proteins, p < 0.0004) and “response to oxidative stress” (4 proteins, p < 0.0005), ranked by p values in StringDB (all pathways listed in Supplementary Table 1). Furthermore, pathway analysis of 30 top consistently upregulated proteins in the panel of cell lines in FITExP indicated the significant enrichment of the “oxidoreductase activity” (details in Supplementary Table 12) (Fig. 3b). The 30 most consistently down-regulated proteins in the panel of cell lines mapped to “nucleosome” and “histone H5” (details in Supplementary Table 13).

Despite differences in proteome responses between different cell lines, the upregulation of proteins involved in glutathione metabolism was observed in all cell lines (Fig. 3c). The upregulation of enzymes involved in glutathione metabolism is in line with glutathione being a backup system for TXNRD1 under oxidative stress conditions [42]. Interestingly, most of the consistently upregulated proteins are Nrf2 target (inducible) genes (bold red in Fig. 3a). Therefore, the other proteins in this list might also be Nrf2 inducible proteins. Inhibition of TXNRD1 typically leads to Nrf2 activation [43], which in turn activates genes involved in the response to oxidative stress such as GCLM and GCLC, which are involved in glutathione (GSH) synthesis [44], among others (Nrf2 inducible proteins upregulated in each cell line are shown in Fig. 3c). In cells treated with auranofin, Nrf2 is strongly activated [45,46]. As shown in Fig. 2c, KEAP1, the other member of the Keap1-Nrf2 cytoprotective pathway was also stabilized by 1.7 °C, but only in cells [47]. The pharmacological activity of auranofin has been shown to be associated with induction of heme oxygenase 1 (HMOX1) [48], which is also an Nrf2-activated gene [49] and upregulated upon TXNRD1 targeting [50]. Indeed, we noticed a 3.6 fold increase in HMOX1 levels in RKO cells, and > 159-fold increase in HCT116 cells. Similarly, HMOX1 levels were almost undetectable in A375 cells before treatment (it was only detected in 1 of the replicates, despite the fact that the protein was identified with 22 unique peptides in other samples), but HMOX1 was reliably quantified after treatment with high intensity, meaning its significant induction. Since HMOX1 has cytoprotective effects, the severe induction of HMOX1 by auranofin might explain why auranofin demonstrates synergistic lethality with HMOX1 inhibitors against chronic lymphocytic leukemia (CLL) [49,50].

### 3.3. Cysteine oxidation in redox proteomics can be linked to protein stability in TPP

The thioredoxin system is responsible for reduction of other cellular proteins by cysteine dithiol-disulfide exchange (schematics in Fig. 4a). Therefore, inhibition of this system by auranofin could lead to stabilization of some redox-sensitive cellular proteins due to structural modulation [27,54]. To be able to compare the changes in the proteome redox state with the thermal stability changes, cells were treated at the same conditions as in TPP over 2 h with 3 μM of auranofin and then subjected to sequential iodoTMT labeling (Fig. 4b). This method will also detect persulfidated cysteine residues [55]. Of the 4459 peptides quantified, 869 had no missing values and were used in subsequent analyses. The overall oxidation level was higher for auranofin than DMSO, as expected, which resulted in an asymmetric volcano plot in Fig. 4c. At least 11 significantly oxidized or reduced peptides belonged to proteins with increased or decreased thermal stability in TPP, respectively (Supplementary Table 14).

The active site of SRXN1, Cys99 (the only cysteine residue in this protein) [56] was more oxidized (aurano/DMSO ratio of 2) (Fig. 4d) and the protein was stabilized by + 4.5 °C in TPP (Fig. 4e). Similarly, the active site of PRDX5, Cys100 [57,58] was less oxidized upon treatment with auranofin (aurano/DMSO ratio of 0.6) (Fig. 4d). and the protein was also less stable in TPP (by −1.7 °C) (Fig. 4e). Other representative proteins with similar behavior are shown in Fig. 4e. Therefore, the combination of TPP and redox proteomics can more reliably identify potential redox regulatory switches in proteins than either of these methods separately.

The 105 significantly oxidized peptides in the redox experiment mapped best to the following KEGG pathways: ribosome, spliceosome, glycolysis/glucoseoneogenesis, metabolic pathways, DNA replication, cell cycle and protein processing in endoplasmic reticulum (the number of pathways is extensive, and the list of proteins can be found in Supplementary Table 7). The 35 significantly reduced peptides mapped most significantly to focal adhesion, adherens junction, ribonucleoprotein complex and proteasome regulatory particle (the list of proteins can be found in Supplementary Table 7).

### 3.4. TPP and FITExP are mostly orthogonal

It is important to assess the complementarity and orthogonality of different chemical proteomics methods. Fig. 5 demonstrates that, in general, protein expression levels used in FITExP are orthogonal to thermal stability in TPP. Some proteins, such as SRXN1, GCLM and GCLC, are altered both in expression and stability upon auranofin treatment. The increased levels of these proteins might be to increased expression rates and/or secondary to stabilization of the proteins followed by increase protein half-lives. As mentioned before, some of these proteins are Nrf2 activated proteins. For example, SRXN1 which is one of the top-regulated proteins in FITExP, was also stabilized in TPP in cells. Other upregulated proteins with simultaneous expression changes and shifts in stability were GCLM and GCLC. OGRF is an...
example of a protein changing only in the stability dimension.

4. Conclusions

In summary, we here used three orthogonal chemical proteomics tools in analyses of the effects of the clinically used redox-active compound auranozin on cultured human cancer cells. We investigated how these techniques performed with respect to de novo deconvolution of drug targets and mechanisms of action. Our comprehensive proteomic signatures can be considered as resources in auranozin research, especially in light of its repurposing potential for cancer treatment. We demonstrated the complementarity of these techniques in identification of the cognate target TXNRD1 and we found NFKB2 and CHORDC1 as additional top targets. The pronounced effects on NFKB2 can in part be downstream of TXNRD1 targeting, with targeting of both proteins contributing to the chemical efficacy of auranozin. Less is known about the potential importance of CHORDC1, which should be studied further. Finally, here we showed that redox proteomics can be efficiently used for studies of downstream redox effects in correlation of protein stability changes with oxidation states of corresponding protein-derived peptides. We conclude that orthogonal chemical proteomics tools should be used in parallel for an increased confidence in identification of drug targets and cellular down-stream effects.

Funding statement

This work was supported by a grant 2015.0063 from KAW to EA and RZ, and 2017–19 from VINNOVA to RZ. A.A.S. would like to acknowledge VINNOVA-funded Research School in Drug Discovery and Development (DDD) for funding his internship in Biochemical and Cellular Assay National facility, Science for Life Laboratory Drug Discovery, Stockholm, Sweden.

Author contributions

P.I.A., K.J., E.S.J.A., and R.A.Z. conceived the project; A.A.S., H.G., B.L., K.J., P.I.A. and R.A.Z., designed the MS experiments; A.A.S., P.S., H.G. and B.L. performed the TPP experiments; A.A.S. and P.S. performed the FITExP, redox proteomics and other MS experiments; A.A.S. and C.M.B. did the data analysis; H.G., B.L., and P.I.A. contributed to the manuscript; A.A.S., E.S.J.A. and R.A.Z. wrote the manuscript.

Declaration of competing interest

Katarina Johansson is currently an employee of Pfizer Innovations AB. The remaining authors declare no conflicts of interest.

Acknowledgements

We are very grateful to Marie Ståhlberg and Carina Palmberg for their assistance in different proteomic experiments.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2020.101491.

References


Fig. 5. Comparison of protein expression vs. thermal stability for HCT116 cells shows the orthogonality of FITExP and TPP. Some Nrf2 target genes are shown in purple. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)